Breakthrough Prize recognition also extended to work identifying a shared genetic cause of ALS and FTD. The coverage credits Rosa Rademakers and Bryan Traynor with identifying the most common genetic driver linking the two neurodegenerative diseases. The advance matters to both research and drug development because it concentrates patient stratification and mechanism hypothesis around a defined genetic pathway. In parallel, it supports the growing industry practice of selecting targets based on genetics rather than only phenotype. For biotech stakeholders, the immediate value is clarity: shared genetics can focus future biomarker strategy, trial enrichment, and therapy design across related neurodegenerative syndromes.